Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 276

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 276
---
 measurements are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The fair value hierarchy has the following levels:

| ● | Level                                                                                    
 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets 
 or liabilities;                                                                          |

| ● | Level                                                                                      
 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that 
 are observable for the asset or liability, either directly (i.e. as prices) or indirectly  
 (i.e. derived from prices); and                                                            |

| ● | Level                                                                                             
 3 - valuation techniques using inputs for the asset or liability that are not based on observable 
 market data (unobservable inputs).                                                                |

F-31 CLEARMIND MEDICINE INC. Notes to the Consolidated Financial Statements (Expressed in United States Dollars)

| 12. | Financial                                   
 Instruments and Risk Management (continued) |

| a. | Fair               
 Values (continued) |

Assets and liabilities measured at fair value on a recurring basis
were presented on the Company’s statement of financial position as of October 31, 2024, as follows:

|                                           |     | Fair                     
 Value Measurements Using |            Quoted 
            prices 
 in active markets 
     for identical 
       instruments 
         (Level 1) |     |   | Significant 
 other       
 observable  
 inputs      
 (Level 2)   |     |   |  Significant 
 unobservable 
       inputs 
    (Level 3) |     |   |     Balance 
 October 31, 
        2024 |
|:------------------------------------------|:----|:-------------------------|------------------:|:----|:--|:------------|:----|:--|-------------:|:----|:--|------------:|
| Short-term investment- shares             |     | $                        |           110,400 |     | $ | –           |     | $ |            – |     | $ |     110,400 |
| Short-term investment- Polyrizon Warrants |     |                          |                 – |     |   | –           |     |   |      178,988 |     |   |     178,988 |
| Derivative warrant liabilities            |     |                          |                 – |     |   | –           |     |   |    3,519,702 |     |   |   3,519,702 |

Assets and liabilities measured at fair